机构：[1]Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China首都医科大学附属安贞医院[2]Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing, China临床科室动脉硬化门诊首都医科大学附属安贞医院[3]School of Medicine, Faculty of Health and Medical Science, University of Western Australia, Perth, WA, Australia[4]Extracorporeal Therapeutic Techniques Unit, Lipid Clinic and Atherosclerosis Prevention Centre, Immunohematology and Transfusion Medicine, "Umberto I" Hospital, Rome, Italy[5]Department of Molecular Medicine, "Sapienza" University of Rome, Rome, Italy[6]Lipid Disorders Clinic, Cardiometabolic Service, Department of Cardiology, Royal Perth Hospital, Perth, WA, Australia
第一作者机构：[1]Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing, China[2]Department of Atherosclerosis, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
推荐引用方式(GB/T 7714)：
Lin Jie,Pang Jing,Wu Xue,et al.AN INTERNATIONAL STUDY OF CARDIOVASCULAR SURVIVAL IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA IN RELATION TO THE USE OF LIPOPROTEIN APHERESIS[J].ATHEROSCLEROSIS SUPPLEMENTS.2018,32:44-44.doi:10.1016/j.atherosclerosissup.2018.04.131.
APA：
Lin, Jie,Pang, Jing,Wu, Xue,Di Giacomo, Serafina,Morozzi, Claudia...&Watts, Gerald F..(2018).AN INTERNATIONAL STUDY OF CARDIOVASCULAR SURVIVAL IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA IN RELATION TO THE USE OF LIPOPROTEIN APHERESIS.ATHEROSCLEROSIS SUPPLEMENTS,32,
MLA：
Lin, Jie,et al."AN INTERNATIONAL STUDY OF CARDIOVASCULAR SURVIVAL IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA IN RELATION TO THE USE OF LIPOPROTEIN APHERESIS".ATHEROSCLEROSIS SUPPLEMENTS 32.(2018):44-44
